Cargando…

Real-world renal function among patients with multiple myeloma in the United States

Detalles Bibliográficos
Autores principales:	Mikhael, Joseph, Singh, Erin, Rice, Megan S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140071/ https://www.ncbi.nlm.nih.gov/pubmed/34021119 http://dx.doi.org/10.1038/s41408-021-00492-6

Ejemplares similares

Real-World Treatment Patterns and Outcomes Among Multiple Myeloma Patients with Asthma and COPD in the United States
por: Rice, Megan S., et al.
Publicado: (2021)

Real‐world multiple myeloma front‐line treatment and outcomes by transplant in the United States
por: Richter, Joshua, et al.
Publicado: (2023)

Systolic dysfunction associated with carfilzomib use in patients with multiple myeloma
por: Jain, Tania, et al.
Publicado: (2017)

Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma
por: Richardson, Paul G., et al.
Publicado: (2021)

The Incidence and Timing of Blood Cultures in Multiple Myeloma – Results from a Retrospective, Single Center, Real-World Study
por: Szabo, Agoston Gyula, et al.
Publicado: (2020)

Real-world Duration of Use and Dosing Frequency of Daratumumab in Patients With Multiple Myeloma in the United States
por: Fonseca, Rafael, et al.
Publicado: (2023)

Large-scale real-life analysis of survival and usage of therapies in multiple myeloma
por: Lopez-Muñoz, N., et al.
Publicado: (2023)

Prognostic value of the Second Revision of the International Staging System (R2-ISS) in a real-world cohort of patients with newly-diagnosed multiple myeloma
por: Yan, Wenqiang, et al.
Publicado: (2023)

Preferences and Priorities for Relapsed Multiple Myeloma Treatments Among Patients and Caregivers in the United States
por: Auclair, Daniel, et al.
Publicado: (2022)

A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab
por: Mikhael, Joseph, et al.
Publicado: (2021)

Incidence of skeletal-related events among multiple myeloma patients in the United States at oncology clinics: Observations from real-world data
por: Kim, Christopher, et al.
Publicado: (2018)

Identification of novel genetic loci for risk of multiple myeloma by functional annotation
por: Macauda, Angelica, et al.
Publicado: (2023)

Arterial thromboembolism in multiple myeloma in the context of modern anti-myeloma therapy
por: Chakraborty, Rajshekhar, et al.
Publicado: (2021)

Identifying “Real” Patients in the Real World
por: Callahan, Sean J.
Publicado: (2020)

Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis
por: Dimopoulos, Meletios A., et al.
Publicado: (2022)

Safety and pharmacokinetic profile of apixaban in end‐stage renal disease: A real‐world analysis
por: Tseng, Chen I., et al.
Publicado: (2022)

Detection of myeloma cell-derived microvesicles: a tool to monitor multiple myeloma load
por: Liu, Zhao-Yun, et al.
Publicado: (2023)

Smoldering Multiple Myeloma Arising in Ulcerative Colitis
por: Yang, Xue, et al.
Publicado: (2018)

Oprozomib in patients with newly diagnosed multiple myeloma
por: Hari, Parameswaran, et al.
Publicado: (2019)

Impact of mitochondrial DNA mutations in multiple myeloma
por: Hoang, Phuc H., et al.
Publicado: (2020)

Real world and hyper reality
por: Gautret, Philippe, et al.
Publicado: (2021)

Multiple myeloma: patient outcomes in real‐world practice
por: Yong, Kwee, et al.
Publicado: (2016)

Reply to Callahan: Identifying “Real” Patients in the Real World
por: Dempsey, Timothy M.
Publicado: (2020)

Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
por: Sivaraj, Dharshan, et al.
Publicado: (2018)

A systematic classification of death causes in multiple myeloma
por: Mai, Elias K., et al.
Publicado: (2018)

Characterization of rare germline variants in familial multiple myeloma
por: Catalano, Calogerina, et al.
Publicado: (2021)

Sensitive multiple myeloma disease monitoring by mass spectrometry
por: Santockyte, Rasa, et al.
Publicado: (2021)

The Landscape of Currently Enrolling Maintenance Trials in Multiple Myeloma
por: Tariq, Syed Maaz, et al.
Publicado: (2023)

Estimating the Population Benefits and Costs of Rituximab Therapy in the United States from 1998 to 2013 Using Real-World Data
por: Danese, Mark D., et al.
Publicado: (2016)

Anticoagulant and Antiplatelet Use Among Hemodialysis Patients in the United States Without Medicare
por: Boggs, Robert, et al.
Publicado: (2022)

Application of the ANCA Renal Risk Score in the United States: A Single-Center Experience
por: Kant, Sam, et al.
Publicado: (2021)

Real World Data on Efficacy and Safety of Vismodegib in Greek Patients with Advanced, Multiple and Metastatic Basal Cell Carcinoma
por: Sgouros, Dimitrios, et al.
Publicado: (2022)

The real-world outcomes of multiple myeloma patients treated with daratumumab
por: Szabo, Agoston Gyula, et al.
Publicado: (2021)

P948: REAL-WORLD EVIDENCE OF BISPHOSPHONATES FOR MULTIPLE MYELOMA
por: Muñoz, Maria Nieves Lopez, et al.
Publicado: (2023)

Multiple myeloma: family history and mortality in second primary cancers
por: Chattopadhyay, Subhayan, et al.
Publicado: (2018)

IgA Type Multiple Myeloma, Clinical Features, and Prognosis
por: Wang, Ling, et al.
Publicado: (2018)

Pharmacokinetics and bioequivalence evaluation of lenalidomide in Chinese patients with multiple myeloma
por: Gao, Tiantao, et al.
Publicado: (2022)

Racial differences as predictors of outcomes in young patients with multiple myeloma
por: Bao, Alicia, et al.
Publicado: (2022)

Infectious complications of bispecific antibody therapy in patients with multiple myeloma
por: Sim, Beatrice Z., et al.
Publicado: (2023)

Compliance With Vaccination Recommendations Among Patients With Multiple Myeloma: A Real World Experience
por: Ludwig, Heinz, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5g1993f1b1pip2kqgjluqj5sad